儿童IgA肾病肾小管间质损害与其他临床病理指标的关系探讨

目的:探讨在儿童IgA肾病中肾小管间质损害与其他临床及病理指标的关系。方法:回顾性分析2014年01月~2017年09月在我院肾活检确诊的119例原发性IgA肾病患者的资料,对比不同程度及类型的肾小管间质损害与其他临床及病理指标之间的关系。结果:肾间质损害总体程度与年龄、性别、体块指数、肉眼血尿发生率、内皮细胞增生程度、肾小球硬化分值、纤维型新月体的发生没有关系。随着肾间质损害的加重,肾小球系膜细胞及基质增殖程度、细胞型及混合型新月体的发生率、尿蛋白的排出量逐渐增高同时肾小球滤过率逐渐下降。间质炎性细胞浸润与内皮细胞增生及细胞型新月体的发生关系密切,而存在肾小管萎缩和肾间质纤维化的患者更容易出现肾小球硬化。结论:IgA肾病患儿的肾小管间质损害与肾小球病变程度相平行,其与肾小球系膜细胞及基质增生程度、新月体形成、与蛋白尿及肾小球滤过率的改变密切相关。不同的小管间质病理类型与其他病理指标的关系各有区别但与各项临床指标的关系没有差别。     

儿童孤立性血尿207例病理分析

目的：探讨小儿孤立性血尿的病理类型.方法：对207例符合孤立性血尿诊断标准的患儿行肾活检术,肾组织进行光镜、电镜及免疫荧光检查.结果：轻微病变72例（34.8%）;正常肾小球61例（29.5%）,其中局灶节段性肾小球透明样变性5例.IgA肾病36例（17.4%）;薄基底膜肾病21例（10.1%）,其中正常肾小球7例,伴轻微病变14例;系膜增生性肾小球肾炎13例（6.3%）,其中伴薄基底膜肾病2例;局灶增生性肾炎4例（1.9%）.结论：轻微病变与正常肾小球占第一位,IgA肾病是小儿表现为肉眼血尿的孤立性血尿的主要原因,但表现为孤立性血尿的IgA肾病病理变化相对较轻,为轻微病变或轻度系膜增生.所有病例均无新月体形成、肾小球硬化和小管间质受累.提示孤立性血尿患儿预后良好.     

伴和不伴新月体形成的IgA肾病的临床与病理研究

目的：探讨伴和不伴新月体形成的原发性IgA肾病（IgAN）临床和病理特点。方法：分析128例经肾活检确诊IgAN患者,分析其临床特点,并根据新月体形成所累及肾小球的比例分组：无新月体形成为A组,69例;≤10%为B组,25例;〉10%〈50%为C组,34例。根据Katafushi积分分析肾脏病理。结果：（1）临床方面：B组和C组的血尿素氮（BUN）较A组高（P〈0.05）;C组血肌酐（Scr）较A组高（P〈0.01）;B组和C组的收缩压（SBP）较A组高（P〈0.01）;C组舒张压（DBP）较A组高（P〈0.01）。（2）病理方面：C组肾小球总积分比A组、B组高（P〈0.01）,B组肾小球总积分比A组高（P〈0.01）;B组球性硬化积分比A组高（P〈0.01）,C组球性硬化积分比A组高（P〈0.01）;C组节段损害、肾小管间质、炎症细胞浸润积分比A组高（P〈0.01）。结论：原发性IgAN随着新月体形成所累及肾小球的比例增加,血压有逐渐升高趋势;肾脏病理损害逐渐加重,故对有新月体形成原发性IgAN应早期干预治疗,以延缓肾病进展。     

儿童毛细血管内皮细胞增生性紫癜性肾炎的临床病理及预后分析

目的 探讨以弥漫性毛细血管内皮细胞增生为主要病理表现的紫癜性肾炎（DEP-HSPN）的临床、病理及预后。 方法 回顾性分析本院近10年来经肾活检确诊的8例DEP-HSPN患儿临床、病理和预后资料,并分别与同病理级别或具有同等蛋白尿水平（肾病水平蛋白尿）的非DEP-HSPN患儿进行比较。 结果 （1）DEP-HSPN起病急,临床表现重,8例患儿中,4例临床表现为肾炎性肾病,3例表现为肾病水平蛋白尿伴血尿,1例呈急性肾炎综合征,4例患儿合并有肉眼血尿。病理分级均为Ⅲ-b级,光镜主要表现为弥漫性毛细血管内皮细胞和系膜细胞增生,常合并毛细血管袢坏死及肾小球内炎性细胞浸润,4例患儿合并细胞性新月体。（2）与病理为Ⅲ-b级的非DEP-HSPN患儿比较,DEP-HSPN患儿病程较短,临床多见肉眼血尿,24 h尿蛋白量高,更多呈肾炎性肾病表现。病理上,DEP-HSPN肾小球毛细血管袢坏死更常见。与具有肾病水平蛋白尿的非DEP-HSPN患儿相比,DEP-HSPN合并新月体的比例较低。（3）8例患儿均采用口服泼尼松联合静脉滴注环磷酰胺（CTX）冲击,病程早期给予2个疗程甲泼尼龙冲击治疗方案。平均随防（7.00±2.20）月,1例临床痊愈,5例持续镜下血尿,2例微量蛋白尿及持续镜下血尿。两组患儿预后差异无统计学意义。 结论 DEP-HSPN起病较急,临床以大量蛋白尿或肾炎性肾病为主要表现,并且常合并肉眼血尿。病程早期给予积极的免疫抑制剂治疗常能取得较满意的近期疗效。     

可溶性血管内皮生长因子受体1在IgA肾病中的临床意义

目的 探讨可溶性血管内皮生长因子受体1 （soluble fms-like tyrosine kinase-1,sFlt-1）在IgA肾病中表达变化的临床意义与病理类型之间的关系.方法 选取2005年1月至2013年3月期间内蒙古自治区医院经肾活检确诊为IgA肾病的80例患者作为病例组,选30名健康献血者作为对照组,测定两组所有人员血浆中sFlt-1表达水平.将80例病例组患者按IgA肾病病理表现分为新月体形成组（36例）及硬化肾小球组（20例）,另有24例IgA肾病患者同时存在新月体形成及硬化肾小球,对比sFlt-1在新月体形成组和硬化肾小球组的相关性.结果 病例组血浆sFlt-1明显高于对照组（P＜0.01）;病例组中新月体形成组的患者血浆中sFlt-1含量明显升高,硬化肾小球组患者血浆中sFlt-1含量相对偏低,sFlt-1与新月体比例呈正相关,而与硬化肾小球比例不相关.结论 检测sFlt-1在IgA肾病中有重要的临床意义,sFlt-1与IgA肾病病理类型有相关性.     

CKD1～2期250例IgA肾病患者临床与病理活动病变的相关性分析

目的：探讨原发性IgA肾病（IgAN）患者临床表现与病理活动病变的关系。方法：将250例经肾活检确诊,慢性肾脏病（CKD）1~2期的IgAN患者,按其临床表现分成3组：表现为镜下血尿或（和）蛋白尿为A组,102例;表现为肉眼血尿为B组,85例;表现为肾病综合征为C组,63例。对比各组临床和病理指标,并进行临床与病理活动病变的相关性分析。结果：（1）各组间资料比较：C组的血IgM、C3、C4水平显著高于A组与B组（P〈0.01）,C3沉积强度显著小于A组与B组（P〈0.01）;（2）临床与病理相关性分析：尿红细胞计数、尿NAG酶与新月体数目、肾小球系膜细胞增生程度呈显著正相关（P〈0.01）,尿NAG酶与肾间质炎细胞浸润程度呈显著正相关（P〈0.01）,尿NAG酶与纤维素样坏死的产生呈正等级相关（P〈0.05）。结论：IgAN的某些临床指标与病理中的活动性病变具有一定的相关性,尿红细胞计数和尿NAG酶是反映病理活动性病变指标,这些指标与新月体数目、肾小球系膜细胞增生、肾间质炎细胞浸润程度呈显著相关性。     

小儿毛细血管内增生性IgA肾病38例临床与病理分析

目的探讨毛细血管内增生性IgA肾病患儿临床与病理之间的关系。方法选择38例肾脏病理诊断为毛细血管内增生性IgA肾病的患儿,分为肾病综合征组和非肾病综合征组以及轻、中、重度内皮细胞增生组,对其尿常规、尿蛋白定量、血清白蛋白等进行检测,对其肾组织中内皮细胞和系膜细胞增生程度进行评分。结果（1）肾病综合征组与非肾病综合征组比较,内皮细胞增生指数偏高,而系膜细胞增生指数无差异。（2）重度与轻度内皮细胞增生组比较,在前驱感染率、肉眼血尿发生率以及尿蛋白好转率上均存在差异,轻、中、重度内皮细胞增生组之间24h尿蛋白定量上均有差异。结论 在小儿毛细血管内增生性IgA肾病患者中,呈肾病综合征表现者有更严重的内皮细胞增生,而其增生程度的轻重与临床中蛋白尿的多寡有关,镜下血尿与内皮细胞增生程度无关,感染似乎是小儿毛细血管内增生性IgA肾病患者发生肉眼血尿的更主要影响因素。     

2型糖尿病合并非糖尿病肾病的临床及病理分析

目的：回顾性分析2型糖尿病合并非糖尿病肾病的临床表现及病理特征。方法：回顾性分析2004年1月～2009年12月临床疑为合并非糖尿病肾病的110例2型糖尿病患者的肾活检资料。根据肾活检结果分为单纯糖尿病肾病（DN）组和糖尿病肾病合并非糖尿病肾病（NDRD）组,并对临床和病理资料进行分析。结果：110例2型糖尿病肾病患者中,50例（45.5%）合并非糖尿病肾病。糖尿病肾病合并非糖尿病肾病组蛋白尿、血尿发生率高于单纯糖尿病肾病组,但糖尿病视网膜病变发生率低于单纯糖尿病肾病组。两组年龄、糖尿病病程、高血压、血肌酐和肾小球滤过率差异无统计学意义。所有合并的非糖尿病肾病中,IgA肾病的比率最高为34%,其他依次为膜性肾病22.0%,系膜增殖性肾小球肾炎14%,HBV相关性肾小球肾炎8.0%,微小病变型肾小球肾炎10%,高血压肾小球硬化4.0%,FSGS4.0%,新月体肾小球肾炎2.0%,狼疮性肾炎2.0%。结论：2型糖尿病肾病合并非糖尿病肾病发生率45.5%,IgA肾病最常见。血尿、蛋白尿同时缺乏糖尿病视网膜病变强烈提示合并非糖尿病肾病。对于临床表现不典型的患者,肾活检是一项排除糖尿病肾脏病变的重要手段。     

伴有新月体形成的原发性IgA肾病的临床与病理特点及预后分析

目的观察伴有新月体形成的原发性IgA肾病的临床、病理特点,分析其对激素及环磷酰胺治疗的反应。 方法收集包头医学院第一附属医院1997年8月至2015年04月收治的80例经肾活检确诊为原发性IgA肾病并伴新月体形成的患者,并依据新月体累及的肾小球比例进行分组,新月体占受累肾小球比例≥50% (A组) 24例;新月体累及的肾小球比例<50%(B组) 56例。肾小球系膜增生、肾小管间质病变采用R.Katafuchi标准积分量化。对两组的临床及病理特点进行比较。治疗方案：将A、B两组再分为单纯糖皮质激素(激素)治疗组,激素＋环磷酰胺治疗组,分别比较不同治疗方案对各组的疗效。A、B组各有24例患者接受了随访。应用SPSS软件进行统计学分析。 结果①临床方面：32例(40%)患者有镜下血尿＋蛋白尿,76例(95%)患者尿蛋白≥2 g/24 h,32例(40%)患者有肉眼血尿;水肿、高血压、肾功能异常者超过半数。A组尿蛋白量及血清肌酐明显高于B组(t＝1.890,t＝2.570; P<0.05),血清白蛋白及肾小球滤过率明显低于B组(t＝2.681, t＝3.014;P<0.05)。②病理方面：所有受累肾小球的新月体面积百分比为5.92%～88.9%,其中A组为52.6%～88.9%, B组为5.92%～48.9%;与B组比较A组肾小管间质损害更严重,两组比较差异有统计学(P<0.05)。③治疗情况：A组及B组经激素或激素＋环磷酰胺治疗后,尿蛋白定量均明显减少(P<0.05) ;单纯激素治疗后A组血清肌酐较治疗前有明显下降(t＝3.243,P<0.05)。随访2～4年时,A组8例患者出现血清肌酐升高,达透析指征,1例死亡;B组2例患者出现血清肌酐升高(1例原有轻度升高,1例新出现血清肌酐升高)。 结论IgA肾病患者随着新月体占受累肾小球比例的增加,肾小管间质病理损害及临床表现亦逐渐加重且预后不佳;激素治疗可减少伴有大新月体形成的原发性IgA肾病的蛋白尿并有可能改善其肾功能。     

小儿毛细血管内增生性IgA肾病的临床与牛津病理分型特点分析

目的：探讨儿童毛细血管内增生性IgA肾病临床特点与牛津病理分型的关系。方法：选取我院肾脏穿刺术后经病理确诊为毛细血管内增生性IgA肾病患儿38例,根据临床特点分为肾病综合征组及非肾病综合征组、肉眼血尿组及非肉眼血尿组,根据尿蛋白定量分为3组,分别为〈2 g组,2 g-3 g组,〉3 g组,分别对牛津分型中系膜细胞增生（M）、内皮细胞增生（E）的分布进行分析,来观察临床与病理之间的关系。结果：内皮细胞增生E1在临床各分组分布中差异均具有统计学意义,而系膜细胞增生M1在临床各分组分布中无差异。结论：在毛细血管增生性IgA肾病的小儿患者中,呈肾病综合征表现的患儿较无肾病综合征表现的患儿有更严重的内皮细胞增生,有肉眼血尿病史的患儿较无肉眼血尿的患儿有更严重的内皮细胞增生,且内皮细胞增生的程度随尿蛋白的增多逐渐加重,而系膜细胞增生与肉眼血尿与否及尿蛋白多寡无明确关系。     

儿童隐匿性肾炎的临床和病理研究

目的：探讨儿童隐匿性肾炎的临床和肾组织病理改变特点及其关系。方法：回顾性分析肾活检的323例隐匿性肾炎患儿的临床和肾组织病理改变情况。结果：323例隐匿性肾炎患儿中，单纯性血尿229例，单纯性蛋白尿19例，血尿伴蛋白尿75例。肾组织病理改变类型包括：轻微病变103例（31，89％）、基本正常74例（22．91％）、IgA肾病（IgAN）73例（22．60％）、薄基底膜病（TBMN）27例（8．36％）、系膜增生性肾炎（MsPGN）18例（5．57％）、局灶增生性肾炎（FPGN）10例（3．10％）、膜性肾病（MN）8例（2，48％）、局灶节段肾小球硬化（舢）8例（2．48％）、微小病变（MCD）1例（0，31％）、IgM肾病（IgMN）1例（0．31％）。单纯性血尿组中肾组织结构基本正常的比例较血尿伴蛋白尿组明显偏高（P〈0，01）；血尿伴蛋白尿组中IgAN的比例高于单纯性血尿组和单纯性蛋白尿组（分别P〈0．01、P〈0．05）。IgAN的Lee分级：单纯性血尿组中Ⅰ、Ⅱ级85．00％，Ⅲ级及以上15．00％；血尿伴蛋白尿组中Ⅰ、Ⅱ级58．10％，Ⅲ级及以上41．90％，明显高于单纯性血尿组（x^2=6．47，P〈0．05）。结论：儿童隐匿性肾炎的病理以轻微病变、基本正常、IgAN为常见表现，血尿伴蛋白尿患儿病变较单纯性血尿患儿为重。     

少量蛋白尿IgA肾病患者镜下血尿与病理指标的相关性分析

目的探索少量蛋白尿IgA肾病(IgAN)患者镜下血尿发生与病理指标的相关性。 方法回顾性分析2007年1月1日至2012年12月31日在解放军总医院经肾穿刺活检首次诊断的原发性IgAN、尿蛋白<0.5 g/24 h且无肉眼血尿患者。采集患者肾穿刺活检前1周内的血压、尿蛋白定量、尿红细胞形态及计数、肾功能等指标。肾活检后的病理指标按照IgAN牛津分型更新版评价,采用Poisson回归分析镜下血尿水平与病理指标的相关性。 结果共纳入尿蛋白<0.5 g/24 h的IgAN患者88例,其中无镜下血尿组22例,非满视野镜下血尿组58例,满视野镜下血尿组8例。Poisson回归分析显示在校正患者的尿蛋白和肾功能(eGFR)水平后,新月体形成(OR 6.55,95%CI 2.68～15.98)和系膜细胞增殖(OR 4.92,95%CI 1.75～13.83)与IgAN患者镜下血尿水平相关,系膜细胞增殖病变与节段硬化或球囊粘连病变存在交互作用(OR 3.82,95%CI 1.30～11.25)。 结论在蛋白尿少于0.5 g/d的IgAN患者中,患者镜下血尿水平相关的病理因素主要是增殖性病变,包括系膜细胞增殖和新月体形成。系膜细胞增殖病变合并节段硬化和(或)球囊粘连病变,与镜下血尿水平的相关性显著增加。     

Recurrence of IgA nephropathy with crescents in kidney transplants

Crescentic IgA nephropathy is an uncommon finding in native kidneys (3%-5%) and in renal transplants. This study was performed to determine the frequency of relapsing crescentic IgA nephropathy after kidney transplantation. Over a 15-year period, 42 patients (25 men, 17 women) of age range 17 to 59 years with biopsy-proven IgA nephropathy in their native kidneys were entered into this retrospective study, because they had undergone kidney transplantation and had sequential allograft biopsies during their follow-up. Mean follow-up after transplantation was 8.9 years (range, 1-15 years). In their native kidneys, 5 patients (12%) had more than 20% crescents, and only 2 (5%) had more than 50% of glomeruli involved. As expected, 52.4% of recipients showed recurrent mesangial IgA deposits in their kidney grafts. The 2 patients with diffuse crescentic IgA nephropathy in their native kidneys experienced acute graft dysfunction at 15 and 47 months. Graft biopsy showed recurrent IgA deposits with cellular crescents in 30% and 20% of glomeruli, respectively. Despite corticosteroid pulse therapy, graft failures occurred 2 and 27 months later. No crescentic proliferation was observed during follow-up in any other case. Only 5 other grafts failed because of chronic allograft nephropathy, without any relationship to the relapse of IgA deposits. These data suggested for the first time that only diffuse crescentic IgA nephropathy in the native kidneys was associated with the occurrence of crescents in the kidney transplants, a finding that raises the possibility of a particular subgroup of IgA nephropathies.     

IgA肾病治疗的思考

IgA肾病是我国最常见的原发性肾小球疾病。主要以IgA免疫球蛋白沉积于肾小球为病理特征;以血尿、蛋白尿、高血压和肾功能损害为主要临床表现。每次血尿和(或)蛋白尿发作是肾小球损伤的标志,如不有效进行干预,可逐渐出现肾功能损害。控制血尿和(或)蛋白尿,降低尿检异常发生的频率,是治疗原发性IgA肾病及防止肾脏慢性化损伤的关键。ACEI/ARB在减少IgA肾病患者的蛋白尿、保护残存肾功能、延缓其进展为终末期肾病等方面优于其他降压药。IgA肾病如有较多新月体形成、明显血尿和蛋白尿,可考虑使用糖皮质激素和(或)与免疫抑制剂。由于IgA肾病是一个慢性化过程,长期随访对改善该病的预后显得尤为重要。     

Active and chronic phases of Berger's disease (IgA nephropathy)

Berger's disease, or IgA nephropathy, is generally considered as pursuing a chronic course, often with recurrent attacks of gross hematuria or persistent microscopic hematuria. However, little attention has been paid to the acute changes that may accompany this nephropathy, and there are few reports of follow-up renal biopsy studies in these patients. We have had the opportunity to study two patients with Berger's disease (IgA nephropathy) in whom initial and follow-up renal biopsy studies were available. Both of these patients presented clinically with gross hematuria and moderately heavy proteinuria. In both cases, the initial renal biopsy disclosed diffuse mesangial proliferation associated with crescent formation, while follow-up biopsy disclosed only mild mesangial proliferation and no crescents. In one case electron microscopy revealed prominent subendothelial and small mesangial deposits in the initial biopsy, which became almost solely large mesangial in the second biopsy. The other case demonstrated only mesangial deposits in both biopsies.     

IgA nephropathy. Evaluation of prognostic factors in patients with moderate disease

Previous studies of IgA nephropathy have demonstrated a number of prognostically significant clinical and pathological factors in groups of patients with the full histological spectrum of the disease. Whether these factors can be applied to a group of IgA nephropathy patients with disease of moderate degree is unknown. Forty patients (9 females, 31 males) with grade III IgA nephropathy (no more than 10% obsolete glomeruli and little or no interstitial fibrosis) were evaluated with respect to age, sex, degree of proteinuria, history of recurrent gross hematuria, hypertension, extent and type of segmental glomerulosclerosis, demonstration of IgG and/or IgM in deposits, presence of peripheral capillary deposits, whether or not there were crescents, and extent of vascular sclerosis. The mean age was 29.6 +/- (SD) 13.1 years. Sixteen patients presented with recurrent gross hematuria, and 24 had microscopic hematuria and proteinuria as the initial manifestation. Hypertension was seen in 5 patients. The mean serum creatinine concentration was 1.09 +/- 0.47 mg/dl (96.4 +/- 41.5 mumol/l), and the mean 24-hour urinary protein was 1.5 +/- 1.3 g. Nine patients had proteinuria greater than or equal to 2.0 g/24 h. Thirty-two patients demonstrated segmental glomerulosclerosis in their biopsies, 13 of which had more than 10% of the glomeruli involved. Seven patients developed established renal failure (Cr greater than or equal to 2.0 mg/dl; 176.8 mumol/l). The 60-and 100-month renal survival rates were 96 and 52%. Life table analysis disclosed that only the degree of proteinuria (greater than or equal to 2.0 g/24 h; p less than 0.05) and the extent of segmental glomerulosclerosis (p less than 0.025) were of prognostic significance.(ABSTRACT TRUNCATED AT 250 WORDS)     

呈局灶节段性肾小球硬化的IgA肾病临床病理特点

目的探讨呈局灶节段性肾小球硬化（FSGS）的IgA肾病（IgAN）的临床和病理特点。方法选取我院1988年1月至2002年2月经肾活检确诊为IgAN的患者587例，其中呈FSGS85例，呈弥漫性系膜增生性肾小球肾炎（MsPGN）162例，呈弥漫性系膜增生性肾小球肾炎伴局灶节段性肾小球硬化（MsPGN伴FSGS）185例，比较3种类型IgAN临床和病理资料。结果FSGS型IgAN占同期所有IgAN的14．5％，临床类型以大量蛋白尿型为主，占37．64％。肾小球球囊黏连发生率高达74．12％，小管间质纤维化发生率97．65％，病理分级以LeeⅣ～Ⅴ级为主，免疫病理以IgA—MG型为主，与MsPGN伴FSGS型和MsPGN型的IgAN相比，FSGS型IgAN病程较长，高血压、肾功能不全发生率较高（P〈0．05），而血尿的发生率与后两者无明显区别。结论呈FSGS型IgAN大量蛋白尿、高血压、肾功能不全的发生率高，病变较重，预后较差。     

Idiopathic IgA nephropathy with diffuse crescent formation

OBJECTIVE: To investigate the clinicopathological features and outcome of idiopathic IgA nephropathy with diffuse crescent formation in Chinese patients. METHODS: Twenty-five patients with diffuse crescentic IgA nephropathy (DCIgAN), 15 males and 10 females with median age of 28.5, and median disease duration of 5.1 months, were studied. Their clinical, laboratory and pathological features and outcome were investigated. Twenty-one were administered pulse immunosuppressive therapy, and 15 were followed up for more than 6 months. RESULTS: 1.14% had total IgA nephropathy, and 16.4% total diffuse crescentic glomerulonephritis. Clinically, most of patients (88%) showed rapidly progressive glomerulonephritis associated with a high level of serum creatinine (418 +/- 264 micromol/l). Gross hematuria was noted in 72%, hypertension in 64%, and nephrotic syndrome in 48%. Pathologically, except for diffuse crescent formation (a median 65% and range 50-95%), we observed segmental necrosis of glomerular capillaries in 60%, glomerular infiltrating cells in 48%, endothelial cells proliferation in 32%, and rupture of Bowmans' capsule in 24%. Severe tubular interstitial damage was also found, tubular atrophy in 64%, interstitial fibrosis in 60%, diffuse interstitial infiltrating cells in 74%, and interstitial vasculitis in 40%. Immunopathologically, four phenotypes were observed; however, IgA associated with IgM deposition was higher than that in patients with general IgA nephropathy (IgAN). In addition, the infiltrating CD4+, CD8+, CD68+ and PCNA+ cells in renal tissue were significantly high compared with that in controls. In a follow-up study, 66.7% of patients had life-sustaining renal function, 4 of them had normal range of serum creatinine (<124 micromol/l), and only 5 were dialysis-dependent. CONCLUSIONS: The patients with crescentic IgA nephropathy mostly show rapidly progressive nephritis associated with more severe pathological changes including glomerular, tubular interstitial and vascular lesions than in patients with general IgAN. The infiltrates in glomeruli may contribute to the crescentic formation, and the intensive immune suppressing treatment is useful to improve renal damage in patients with DCIgAN.     

强直性脊柱炎相关IgA肾病临床病理分析

目的了解强直性脊柱炎（AS）相关IgA肾病的临床病理特点。方法自1997年1月至2006年12月10年间在北京协和医院接受肾活检确诊为IgA肾病的AS患者10例，回顾性分析其临床及病理特点。结果男性9例，女性l例，平均年龄（28．6＋6．8）岁（16～53岁）。4例患者表现为无症状镜下血尿；6例表现反复血尿合并蛋白尿，其中2例有发作性肉眼血尿。平均尿蛋白量（24h）为（1．56±1．53）g（0．02-5．26g）。2例患者有血压升高。所有患者的血肌酐水平均在正常范围。光镜下，8例患者呈轻度系膜细胞增生，IgA肾病Lee氏分级均为Ⅰ或Ⅱ级；另外2例呈中重度系膜增生性改变，IgA肾病Lee氏分级分别为Ⅲ级和Ⅵ级。结论AS相关IgA肾病临床表现为隐匿性肾炎或慢性肾小球肾炎，病理改变以轻度系膜增生为主。